Top Abstracts with Expert Perspective: Myeloma/CLL
Tracks
Track 5
| Monday, April 29, 2024 |
| 3:00 PM - 4:30 PM |
| Room 4 |
Speaker
Dr Talha Munir
Consultant
Leeds Teaching Hospitals NHS Trust
Extended Follow-up of the Phase 3 ALPINE Study of Zanubrutinib Versus Ibrutinib in R/R CLL/SLL
3:00 PM - 3:15 PM
Dr Piers Patten
Clinical Senior Lecturer
King's College London
Sonrotoclax (BGB-11417) + Zanubrutinib in Patients With Treatment-Naive CLL/SLL: An Ongoing Phase 1/2 Study
3:15 PM - 3:30 PM
Prof. George Follows
Consultant Haematologist
Cambridge University Hospitals NHS Trust
Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: Elevate-TN 6-year Follow-Up
3:30 PM - 3:45 PM
Dr. Angela Hamblin
Consultant Haematologist
Oxford University Hospitals NHS Foundation Trust
NHS-Ready Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients
3:45 PM - 4:00 PM
Dr Surita Dalal
Postdoctoral Research Fellow
Leeds Teaching Hospitals NHS Trust
NCRI FLAIR Trial: Assessment of mutational landscape of CLL patients at baseline and prognostic impact.
4:00 PM - 4:15 PM
Dr. Emma Searle
Consultant Haematologist
The Christie NHS Foundation Trust
Elranatamab in patients with relapsed or refractory multiple myeloma: updated efficacy and safety from MagnetisMM-3
4:15 PM - 4:30 PMChair
Dean Smith
Associate Professor And Honorary Consultant
Nottingham University Hospitals NHS Trust
